Kalvista Pharmaceuticals (KALV) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Kalvista Pharmaceuticals (NASDAQ:KALV) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $30.00 price target on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research raised Kalvista Pharmaceuticals from a hold rating to a buy rating and set a $19.00 price objective for the company in a research note on Wednesday, September 12th. ValuEngine raised Kalvista Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 2nd. Roth Capital initiated coverage on Kalvista Pharmaceuticals in a research note on Tuesday, July 10th. They set a buy rating and a $20.00 price objective for the company. Stifel Nicolaus initiated coverage on Kalvista Pharmaceuticals in a research note on Monday, October 15th. They set a buy rating for the company. Finally, BidaskClub lowered Kalvista Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, October 9th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $25.25.

NASDAQ:KALV traded up $0.16 during trading hours on Tuesday, hitting $18.70. 9,016 shares of the company’s stock traded hands, compared to its average volume of 114,566. The firm has a market capitalization of $323.31 million, a price-to-earnings ratio of -12.22 and a beta of 3.02. Kalvista Pharmaceuticals has a 52 week low of $7.73 and a 52 week high of $23.97.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.14). The business had revenue of $3.72 million for the quarter, compared to the consensus estimate of $4.11 million. Kalvista Pharmaceuticals had a negative net margin of 132.38% and a negative return on equity of 56.24%. On average, equities analysts predict that Kalvista Pharmaceuticals will post -2.11 earnings per share for the current year.

In other news, Director Albert Cha purchased 1,058,824 shares of the company’s stock in a transaction on Monday, September 10th. The stock was purchased at an average price of $17.00 per share, with a total value of $18,000,008.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 38.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of KALV. Spark Investment Management LLC bought a new stake in Kalvista Pharmaceuticals during the second quarter worth about $108,000. BlackRock Inc. lifted its stake in Kalvista Pharmaceuticals by 203.8% during the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 10,871 shares during the last quarter. DRW Securities LLC lifted its stake in Kalvista Pharmaceuticals by 37.3% during the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 5,600 shares during the last quarter. Stanley Laman Group Ltd. lifted its stake in Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 21,861 shares during the last quarter. Finally, Interwest Venture Management Co. lifted its stake in Kalvista Pharmaceuticals by 17.8% during the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock worth $8,596,000 after purchasing an additional 58,824 shares during the last quarter. 37.12% of the stock is owned by hedge funds and other institutional investors.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: Why does a company issue an IPO?

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply